A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors
The purpose of the study is to learn more about AMG650 (from here on referred to as the study drug) in people with advanced solid tumor with a specific type of mutation. We are hoping to gather information on the safety and tolerability (good and bad effects) of the study drug.
Triple Negative Breast Cancer
Platinum-Resistant High Grade Serous Ovarian Cancer, primary peritoneal cancer and/or fallopian-tube cancer
Serous Endometrial Cancer
Advanced or metastatic solid tumor with TP53MUT (Dose Exploration only, as assessed by local testing)
1. Individuals 18 years or older
2. Adequate organ function
3. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
The length of your participation in this study will depend on how long you receive the study drug. For participants who completes the entire study from the date of informed consent through completion of safety follow-up or long term follow-up period, the duration of the study will be approximately 2 years to complete.
Knight Clinical Trials Information Line